Utilização do secretoma como uma terapia regenerativa acelular no tratamento da pneumonia decorrente da infecção pela SARS-CoV-2 (COVID-19)
DOI:
https://doi.org/10.11606/issn.1679-9836.v102i6e-210936Palavras-chave:
SARS-Cov-2, Coronavírus, Células-tronco mesenquimais, Secretoma, PneumoniaResumo
O campo da ciência relacionado a biologia das células-tronco tem se mostrado extremamente promissora nos últimos anos. Dentre os diversos ramos, a abordagem terapêutica que envolve as moléculas bioativas secretadas pelas células-tronco mesenquimais (CTMs) mais comumente chamado de secretoma, vem sendo alvo de especial atenção. O fato de ser uma abordagem acelular tem levado os pesquisadores a torná-la mais eficaz. Dentre os possíveis alvos estão as lesões respiratórias na qual se inclui a pneumonia característica clínica decorrente da infecção por coronavírus (CoVs). Neste trabalho abordamos o estado da arte e o potencial terapêutico do secretoma no tratamento de pacientes acometidos por pneumonia em decorrência da infecção pela SARS-CoV-2 (severa síndrome respiratória aguda derivada do coronavírus 2).
Downloads
Referências
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med. 2020;382(8):692-94. Doi: 10.1056/NEJMp2000929.
Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1(7428):76-7. Doi: 10.1016/s0140-6736(66)92364-6.
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23. Doi: 10.1007/978-1-4939-2438-7_1.
Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8 Suppl(Suppl 1):S9-14. Doi: 10.1046/j.1440-1843.2003.00518.x.
Yang M, Li CK, Li K, Hon KLE, Ng MHL, Chan PKS, et al. Hematological findings in SARS patients and possible mechanisms. Int J Mol Med. 2004;14(2):311-15. doi:10.3892/ijmm.14.2.311.
Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J. 2005;24(11 Suppl):S223-7, discussion S226. Doi: 10.1097/01.inf.0000188166.17324.60.
World Health Organization.VPVID-19.
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-20. Doi: 10.1056/NEJMoa1211721.
Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752-61. Doi: 10.1016/S1473-3099(13)70204-4.
World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2022 Outubro 28]. http://www.who.int/emergencies/mers-cov.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. Doi: 10.1016/S0140-6736(20)30251-8.
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-7. Doi: 10.1002/jmv.25689.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11. Doi: 10.1186/s40779-020-00240-0.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. Doi: 10.1001/jama.2020.2648.
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-82. Doi: 10.7326/M20-0504.
Ferguson N, Laydon D, Nedjati-Gilani G, Imai G, Ainslei N, Baguelin K, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID- 19 mortality and healthcare demand. Imperial College COVID-19 Response Team. 2020. 16 March. Doi:10.25561/77482.
Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656-7. Doi: 10.1016/S1473-3099(20)30232-2.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. Doi: 10.1038/s41586-020-2008-3.
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92. Doi: 10.1038/s41579-018-0118-9.
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016;24(6):490-502. Doi: 10.1016/j.tim.2016.03.003.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. Doi: 10.1038/s41586-020-2012-7.
Caplan AI, Hariri R. Body Management: Mesenchymal Stem Cells Control the Internal Regenerator. Stem Cells Transl Med. 2015;4(7):695-701. Doi: 10.5966/sctm.2014-0291.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. Doi: 10.1080/14653240600855905.
Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 2010;19(6):667-79. Doi: 10.3727/096368910X508762.
Damania A, Jaiman D, Teotia AK, Kumar A. Mesenchymal stromal cell-derived exosome-rich fractionated secretome confers a hepatoprotective effect in liver injury. Stem Cell Res Ther. 2018;9(1):31. Doi: 10.1186/s13287-017-0752-6.
Julianto I, Rindastuti Y. Topical Delivery of Mesenchymal Stem Cells “Secretomes” in Wound Repair. Acta Med Indones. 2016;48(3):217-20.
Mitchell R, Mellows B, Sheard J, Antonioli M, Kretz O, Chambers D, et al. Secretome of adipose-derived mesenchymal stem cells promotes skeletal muscle regeneration through synergistic action of extracellular vesicle cargo and soluble proteins. Stem Cell Res Ther. 2019;10(1):116. Doi: 10.1186/s13287-019-1213-1.
Carter K, Lee HJ, Na KS, Fernandes-Cunha GM, Blanco IJ, Djalilian A, et al. Characterizing the impact of 2D and 3D culture conditions on the therapeutic effects of human mesenchymal stem cell secretome on corneal wound healing in vitro and ex vivo. Acta Biomater. 2019;99:247-57. Doi: 10.1016/j.actbio.2019.09.022.
Beer L, Mildner M, Ankersmit HJ. Cell secretome based drug substances in regenerative medicine: when regulatory affairs meet basic science. Ann Transl Med. 2017;5(7):170. Doi: 10.21037/atm.2017.03.50.
Barbas CSV, Matos GFJ. Síndrome do Desconforto Respiratório Agudo: Definição. Pulmão. Rio de Janeiro. 2011:20(1) 6p.
Ricardo JJ, Ari M. COVID-19 Cytocine storm th interplay between inflamation and coagulation. Lancet. Respir Med, 2020;8(6):E46-E47. Doi: 10.1016/S2213-2600(20)30216-2.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. Doi: 10.1016/S0140-6736(20)30628-0.
O’Dwyer DN, Gurczynski SJ, Moore BB. Pulmonary immunity and extracellular matrix interactions. Matrix Biol. 2018;73:122-34. Doi: 10.1016/j.matbio.2018.04.003.
Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):1362-9. Doi: 10.1182/blood-2006-12-063412.
Liao J, Chen X, Li Y, Ge Z, Duan H, Zou Y, et al. Transfer of bone-marrow-derived mesenchymal stem cells influences vascular remodeling and calcification after balloon injury in hyperlipidemic rats. J Biomed Biotechnol. 2012;2012:165296. Doi: 10.1155/2012/165296.
Toh WS, Lai RC, Hui JHP, Lim SK. MSC exosome as a cell-free MSC therapy for cartilage regeneration: Implications for osteoarthritis treatment. Semin Cell Dev Biol. 2017;67:56-64. Doi: 10.1016/j.semcdb.2016.11.008.
Damania A, Jaiman D, Teotia AK, Kumar A. Mesenchymal stromal cell-derived exosome-rich fractionated secretome confers a hepatoprotective effect in liver injury. Stem Cell Res Ther. 2018;9(1):31. Doi: 10.1186/s13287-017-0752-6.
Cunningham CJ, Redondo-Castro E, Allan SM. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. J Cereb Blood Flow Metab. 2018;38(8):1276-92. Doi: 10.1177/0271678X18776802.
Bochon B, Kozubska M, Surygała G, Witkowska A, Kuźniewicz R, Grzeszczak W, et al. Mesenchymal Stem Cells-Potential Applications in Kidney Diseases. Int J Mol Sci. 2019;20(10):2462. Doi: 10.3390/ijms20102462.
Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore). 2020;99(31):e21429. Doi: 10.1097/MD.0000000000021429.
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11(2):216-28. Doi: 10.14336/AD.2020.0228.
Zhu YG, Feng XM, Abbott J, Fang XH, Hao Q, Monsel A, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 2014;32(1):116-25. Doi: 10.1002/stem.1504.
Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, O›Kane CM, et al. Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer. Am J Respir Crit Care Med. 2017;196(10):1275-86. Doi: 10.1164/rccm.201701-0170OC.
De Castro LL, Xisto DG, Kitoko JZ, Cruz FF, Olsen PC, Redondo PAG, et al. Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma. Stem Cell Res Ther. 2017;8(1):151. Doi: 10.1186/s13287-017-0600-8.
Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, Stolk J, Hiemstra PS. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018;73(6):565-74. Doi: 10.1136/thoraxjnl-2017-210672.
Fujita Y, Kadota T, Araya J, Ochiya T, Kuwano K. Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases. J Clin Med. 2018;7(10):355. Doi: 10.3390/jcm7100355.
Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies. Front Immunol. 2017;8:339. Doi: 10.3389/fimmu.2017.00339.
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020;29(12):747-54. Doi: 10.1089/scd.2020.0080.
Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, et al. Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit Care Med. 2015;192(3):324-36. Doi: 10.1164/rccm.201410-1765OC.
Putra A, Widyatmoko A, Ibrahim S, Amansyah F, Amansyah F, Berlian MA, et al. Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. F1000Res. 2021;10:228. Doi: 10.12688/f1000research.51191.2.
Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, Makarem J, Nasiri R, Salahshour F, Dehghan-Manshadi SA, et al. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Stem Cell Res Ther. 2022;13(1):96. Doi: 10.1186/s13287-022-02771-w.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2023 Enrico Jardim Clemente Santos, Angela
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
